Search Results
Your search for ,led matches 5952 pages
Showing 601 - 650Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit
An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer,...
Gedatolisib Plus Palbociclib and Endocrine Therapy in HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in The Lancet Oncology by Layman et al, findings in dose-expansion groups of a phase Ib trial indicated activity of the pan-PI3K–mTOR inhibitor gedatolisib in combination with palbociclib and endocrine therapy in patients with hormone receptor (HR)-positive, HER2-negative advanced...
ASCO Congratulates 2024 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2024 ASCO Annual Meeting. The 2024 Special Award Recipients...
Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER) antagonist and degrader giredestrant did not significantly improve progression-free survival vs physician’s choice of endocrine...
Pazopanib in Patients With Metastatic Renal Cell Carcinoma and No Evidence of Disease After Metastasectomy
As reported in the Journal of Clinical Oncology by Leonard J. Appleman, MD, PhD, and colleagues, the phase II ECOG-ACRIN E2810 trial showed no significant improvement in disease-free survival with pazopanib vs placebo in patients with metastatic renal cell carcinoma with no evidence of disease...
T-DXd in HER2-Overexpressing Unresectable or Metastatic NSCLC
As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer (NSCLC) cohorts of the phase II DESTINY-Lung01 trial show activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in this setting. Prior ...
Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Domenica Lorusso, MD, PhD, and colleagues, the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial has shown that the addition of pembrolizumab to chemoradiotherapy improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced...
Eligibility for and Prevalence of Lung Cancer Screening in the United States in 2022
In a study reported in a research letter in JAMA Network Open, Henderson et al identified prevalence of lung cancer screening in the United States in 2022 using U.S. Preventive Services Task Force (USPSTF) 2021 and 2013 recommendations for screening eligibility. The USPSTF 2013 guidelines...
Inotuzumab Ozogamicin for Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, inotuzumab ozogamicin (Besponsa) was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting Efficacy Data Approval was based on findings in the ITCC-059 trial (ClinicalTrials.gov...
Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations
On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved...
Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma
On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. This represents the first U.S. ...
Early Breast Cancer: Nurse-Led Follow-up Intervention and Quality of Life After Treatment
In a Danish single-institution phase III trial (MyHealth) reported in the Journal of Clinical Oncology, Saltbæk et al found that nurse-led individualized follow-up was associated with significantly better breast cancer–specific quality of life compared with usual care after completion of primary...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer
On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind...
Dostarlimab-Based Combinations in Advanced Endometrial Cancer
Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking...
Early Breast Cancer: Adding Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy
As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of adjuvant ribociclib to a nonsteroidal aromatase inhibitor (NSAI) in patients with...
From Fatal to Fearless: How Patients Can Take Control of Their Disease and Fear Cancer Less
In 1996, at the age of 37, Kathy Giusti was diagnosed with the incurable blood cancer multiple myeloma and told she had about 3 years to live. In the mid-1990s, effective therapies for this second most common blood cancer were nearly nonexistent. Standard of care for myeloma consisted of oral...
Expert Point of View: Luis Paz-Ares, MD, PhD
The findings from RATIONALE-315 were discussed at the ESMO (European Society for Medical Oncology) Virtual Plenary by Luis Paz-Ares, MD, PhD, Head of the Medical Oncology Service at the Hospital Universitario 12 de Octubre, Madrid. He noted that inhibitors of PD-1 and its ligand PD-L1, as...
In Resectable Non–Small Cell Lung Cancer, Perioperative Use of Tislelizumab Alone or With Chemotherapy Improved Outcomes
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment involving the checkpoint inhibitor tislelizumab led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the phase III RATIONALE-315 trial...
Is Hypofractionated Radiotherapy Emerging as the New Standard of Care After Prostatectomy?
It is currently acknowledged that hypofractionated radiotherapy, an increasingly favored approach in prostate cancer treatment, delivers higher radiation doses over fewer sessions compared with conventional fractionation schedules. This approach is supported by the recognition that prostate cancer ...
Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia
As reported in The Lancet Oncology by Kater et al, the phase IIIb VENICE-1 trial has shown activity of venetoclax monotherapy in adult patients with relapsed or refractory chronic lymphocytic leukemia, including those with prior B-cell receptor–associated kinase (BCR) inhibitor treatment. Study...
Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
On February 13, 2024, the U.S. Food and Drug Administration approved liposomal irinotecan (Onivyde) for use with oxaliplatin, fluorouracil, and leucovorin in the first-line treatment of metastatic pancreatic adenocarcinoma.1 Supporting Efficacy Data Approval was based on the open-label NAPOLI 3...
CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities
Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...
Cabozantinib Plus Atezolizumab Improves Progression-Free Survival
The combination of the tyrosine kinase inhibitor cabozantinib (multiple targets, including MET, AXL, VEGFR2, RET, and FLT ) plus the monoclonal antibody atezolizumab achieved statistically significant improvement in progression-free survival compared with second-line novel hormonal therapy in...
Lillian L. Siu, MD, FRCPC, FASCO, FAACR, Named 2024–2025 AACR President-Elect
The American Association for Cancer Research (AACR) announced that its members have elected Lillian L. Siu, MD, FRCPC, FASCO, FAACR, as the 2024–2025 President-Elect of the AACR. Professional and Research Background Dr. Siu currently serves as Professor of Medicine at the University of Toronto; as ...
Enfortumab Vedotin Plus Pembrolizumab Yields Benefit in Key Subgroups With Advanced Urothelial Cancer
The combination of the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab achieved favorable rates of progression-free survival, overall survival, and objective responses compared with chemotherapy among key subgroups of patients with previously...
Previously Untreated Advanced Urothelial Cancer: Antibody-Drug Conjugate Plus PD-1 Inhibitor
As reported in The New England Journal of Medicine by Thomas Powles, MD, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody-drug conjugate enfortumab vedotin-ejfv and the PD-1 inhibitor pembrolizumab improved progression-free and overall survival vs...
From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research
Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...
Sunitinib in Metastatic Progressive Pheochromocytomas and Paragangliomas
In a phase II trial (FIRSTMAPPP) reported in The Lancet, Eric Baudin, MD, and colleagues found that the multikinase inhibitor sunitinib was active in patients with metastatic progressive pheochromocytomas and paragangliomas. As stated by the investigators, “No randomized controlled trial has ever...
Benefit of Belantamab Mafodotin–Based Regimen Supported in Multiple Myeloma
Positive results with the use of belantamab mafodotin-blmf in the phase III DREAMM-7 study were presented during the ASCO Plenary Series: February 2024.1 In relapsed or refractory multiple myeloma, DREAMM-7 evaluated the use of the regimen belantamab mafodotin, bortezomib, and dexamethasone (BVd)...
Long-Term Follow-up Affirms Benefit of Pembrolizumab Plus Chemotherapy in Advanced Esophageal Cancer
Long-term follow-up of the phase III KEYNOTE-590 trial confirms the benefit of the PD-1 inhibitor pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median of follow-up of almost 59 months, patients treated with the chemoimmunotherapy...
Studies Show Progress in Using ctDNA to Guide Colorectal Cancer Treatment
Circulating tumor DNA (ctDNA) has become an established biomarker of measurable or molecular residual disease (MRD) after curative-intent surgery in patients with colorectal cancer. The research focus is now on linking ctDNA to long-term outcomes and using it to guide treatment decisions—which was...
Nivolumab Plus Ipilimumab Improves Progression-Free Survival in First-Line Setting of Metastatic Colorectal Cancer
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) nonresectable or metastatic colorectal cancer derived significant benefit from an immunotherapy doublet, with nivolumab plus ipilimumab reducing the...
Esophageal Squamous Cell Cancer: Overall Survival Improved With Tiragolumab and Atezolizumab Plus Chemotherapy
For patients with treatment-naive, locally advanced or metastatic esophageal squamous cell carcinoma, the addition of two checkpoint inhibitors to chemotherapy significantly improved not only progression-free survival but also overall survival, in the randomized, phase III SKYSCRAPER-08 trial...
Five New Cancer Grand Challenges Teams Named in Global Effort to Resolve Hurdles in Cancer Research
The Cancer Grand Challenges initiative announced it has selected five new global teams that will each receive up to $25 million in funding over the course of 5 years to address four major challenges faced by cancer research. Background In March 2023, the initiative unveiled nine new challenges to...
Patients With Early-Stage HR-Positive Breast Cancer May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Newly published study results revealed that use of the Breast Cancer Index (BCI) test led to physicians changing their long-term antiestrogen treatment recommendations for 40% of patients with early-stage hormone receptor–positive breast cancer. The results, which suggest that many women may be...
Physician Attitudes Toward 2020 ACS Cervical Cancer Screening Guidelines
Investigators have uncovered that despite low adoption rates of the 2020 American Cancer Society (ACS) cervical cancer screening guidelines among physicians, a majority of them expressed willingness to utilize the recommendations under certain circumstances, according to a recent study published by ...
Novel CD123-Targeting Antibody-Drug Conjugate in Relapsed or Refractory AML
In a phase I/II study reported in The Lancet Oncology, Naval Daver, MD, and colleagues found that pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, showed activity in patients with CD123-positive relapsed or refractory acute myeloid leukemia (AML). Study Details...
Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of Ro-CHOP Trial
As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously...
Highlights From the 2023 San Antonio Breast Cancer Symposium
Studies presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) significantly moved the needle forward in our treatment of breast cancer. We are increasingly learning how to stratify risk, so we can optimize therapy and minimize our patients’ exposure to treatments that will not be...
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in patients with early-stage, high-risk, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to updated results of the phase III...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Stool-Based Colorectal Cancer Screening: Comparison of Fecal Immunochemical Tests
In a Dutch study reported in The Lancet Oncology, Wisse et al found that a multitarget fecal immunochemical test (mtFIT) improved detection of advanced adenomas vs standard FIT in colorectal cancer screening. The mtFIT used in the study measures hemoglobin, calprotectin, and serpin family F member...
AACR Cancer Centers Alliance Formed
Under the leadership of preeminent U.S. cancer center directors, the American Association for Cancer Research (AACR) recently announced the formation of an innovative initiative, the AACR Cancer Centers Alliance. The Alliance will bring together the nation’s cancer centers, with the goal of...
Exploring the Role of Intravenous Mistletoe Extract in Treating Metastatic Solid Tumors
Guest Editor’s Note: The use of mistletoe extract to support systemic therapy and improve quality of life for patients with cancer, though common, remains controversial. Promising results have been reported, but largely in trials that were not placebo-controlled nor properly randomized. In this...
ASCO Remembers Humanitarian and Health Equity Champion Edith P. Mitchell, MD
ASCO is deeply saddened by the death of oncology luminary, health equity champion, and ASCO Humanitarian Award honoree Edith P. Mitchell, MD, MACP, FCCP, FRCP (London), on January 21, 2024. At the time of her passing, Dr. Mitchell was Director of the Center to Eliminate Cancer Disparities,...
Preventing Cancer Should Not Mean Sacrificing Quality of Life
My family first suspected we might have inherited the BRCA1/2 gene mutation after my father was diagnosed with his third cancer, colorectal cancer, following multiple bouts of squamous cell carcinoma and basal cell carcinoma beginning in his 30s and later prostate cancer. But the high risk of...
Belzutifan: New Standard in Previously Treated Renal Cell Carcinoma
Belzutifan is a first-in-class, oral hypoxia-inducible factor (HIF)-2α inhibitor, and active HIF-2α is a key oncogenic driver in clear cell renal cancer. The manufacturer has filed a new drug application for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1– and...
Evaluating the Use of Perioperative Chemoimmunotherapy in Resectable Gastric and Gastroesophageal Junction Cancers
Updates of two key phase III trials presented at the 2024 ASCO Gastrointestinal Cancers Symposium showed the benefit of adding a checkpoint inhibitor to standard perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) in locally advanced, resectable gastric and...
For Unresectable Liver Cancer, the Addition of Durvalumab and Bevacizumab Boosts Efficacy of Transarterial Chemoembolization
Patients with unresectable hepatocellular carcinoma derived significant benefit from the addition of the monoclonal antibody durvalumab and the angiogenesis inhibitor bevacizumab to transarterial chemoembolization (TACE), which alone has been a standard of care for 20 years. Investigators of the...
